Diabetes mellitus is a systemic metabolic disorder with important vascular consequences. Cardiovascular disease remains among its most serious complications and includes coronary artery disease, myocardial infarction, heart failure, cerebrovascular disease and peripheral arterial disease. The mechanisms underlying diabetic cardiovascular disease are multifactorial and involve hyperglycaemia, dyslipidaemia, insulin resistance, oxidative stress, inflammation, endothelial dysfunction, renal impairment and abnormalities in thrombosis. Renal dysfunction is particularly relevant because diabetes is a major cause of chronic kidney disease, and the coexistence of diabetes and renal impairment substantially increases cardiovascular risk. Serum creatinine and estimated glomerular filtration rate provide information regarding filtration function, whereas urinary albumin excretion reflects both renal injury and systemic vascular dysfunction. The source thesis emphasizes that albuminuria and reduced eGFR are associated with systemic endothelial dysfunction, inflammation, oxidative stress and accelerated atherosclerosis, and therefore act as both renal and cardiovascular markers. Albuminuria has special importance because increased urinary albumin excretion may be associated with cardiovascular risk even before substantial reduction in glomerular filtration develops. The urinary albumin-to-creatinine ratio offers a practical method of detecting abnormal albumin excretion in a spot urine sample and is routinely applicable in tertiary care practice. Serum uric acid has also attracted attention as a cardiometabolic biomarker. Hyperuricaemia commonly coexists with obesity, insulin resistance, hypertension and chronic kidney disease. Elevated uric acid may be associated with oxidative stress, endothelial dysfunction, vascular inflammation and activation of the renin-angiotensin system. Nevertheless, its interpretation is complicated by the influence of renal function, diet and medications. Inflammation represents another important pathway. Atherosclerosis is increasingly recognized as a chronic inflammatory disease. High-sensitivity C-reactive protein is a marker of low-grade systemic inflammation and has been investigated in relation to metabolic syndrome, diabetes, endothelial dysfunction and cardiovascular disease. The source thesis proposes that no single biochemical marker adequately represents the complex pathophysiology of cardiovascular disease in diabetes. HbA1c represents glycaemic exposure, lipid parameters represent atherogenic burden, UACR and eGFR reflect cardiorenal involvement, hs-CRP reflects inflammation, while troponins and natriuretic peptides may indicate myocardial injury and stress. Accordingly, the present study evaluated renal, metabolic and inflammatory biochemical markers and examined whether combinations of biomarkers might improve discrimination of cardiovascular complications among patients with diabetes mellitus. Aim To evaluate renal, metabolic and inflammatory biochemical predictors associated with cardiovascular complications in patients with diabetes mellitus.

The study was designed as a hospital-based observational, analytical, cross-sectional study comparing diabetic patients with cardiovascular complications against diabetic patients without cardiovascular complications. Study Setting The study was conducted in the Department of Biochemistry in collaboration with clinical departments at Amaltas Institute of Medical Sciences. Biochemical investigations were performed using standard laboratory procedures with appropriate quality-control measures. Study Population Adult patients with diabetes mellitus attending the outpatient departments or admitted to participating inpatient departments were considered for inclusion. Participants were classified into: Group I: Patients with diabetes mellitus and documented cardiovascular complications. Group II: Patients with diabetes mellitus without documented cardiovascular complications. Cardiovascular complications described in the source protocol included coronary artery disease, acute coronary syndrome, previous myocardial infarction, ischaemic heart disease, heart failure, cerebrovascular disease/ischaemic stroke and peripheral arterial disease. For the illustrative results in the thesis, 200 patients were considered, equally divided between the two groups. Renal Biochemical Assessment Serum creatinine was measured using a kinetic Jaffe method or enzymatic method according to the standardized institutional protocol. eGFR was calculated using an appropriate validated creatinine-based equation. UACR was derived from urinary albumin and urinary creatinine measured in a spot urine sample. Serum Uric Acid Serum uric acid was measured using an enzymatic uricase method on an automated clinical chemistry analyser and expressed in mg/dL. High-Sensitivity C-Reactive Protein Where included in the study protocol, hs-CRP was determined using a validated high-sensitivity immunoturbidimetric or immunoassay method and expressed in mg/L. Statistical Analysis Continuous variables were expressed as mean±standard deviation or median with interquartile range as appropriate. Between-group comparisons were performed using the independent-samples Student's t-test or Mann-Whitney U test. Categorical variables were analysed using the chi-square or Fisher's exact test. Binary logistic regression was used to identify independent biochemical predictors of cardiovascular complications. Potential predictors included HbA1c, lipid parameters, serum creatinine, eGFR, UACR, serum uric acid and hs-CRP. Relevant confounding factors included age, sex, duration of diabetes, BMI, hypertension, smoking and treatment-related variables. Adjusted odds ratios with 95% confidence intervals were calculated. Receiver operating characteristic analysis was used to assess discriminatory ability. AUC, sensitivity and specificity were evaluated for individual and combined markers.

The source document explicitly states that its numerical results are illustrative examples developed for thesis formatting and statistical presentation and are not actual study findings. Table 1. Comparison of Renal Biochemical Parameters Between Diabetic Patients With and Without Cardiovascular Complications Parameter With CVD (Mean ± SD) Without CVD (Mean ± SD) p-value Serum urea (mg/dL) 41.8 ± 15.2 32.7 ± 11.8 <0.001 Serum creatinine (mg/dL) 1.28 ± 0.46 0.96 ± 0.29 <0.001 eGFR (mL/min/1.73 m²) 69.4 ± 19.7 86.6 ± 18.3 <0.001 UACR (mg/g) 112.6 ± 96.5 48.3 ± 61.7 <0.001 Patients with cardiovascular complications demonstrated significantly worse renal biochemical profiles. Serum urea and creatinine were significantly higher, while mean eGFR was substantially lower. UACR was more than twice as high in the CVD group, indicating a strong association between albuminuria and cardiovascular complications. Table 2. Independent Biochemical Predictors of Cardiovascular Complications Predictor Adjusted OR 95% CI p-value HbA1c, per 1% increase 1.58 1.18–2.12 0.002 LDL-C, per 10 mg/dL increase 1.16 1.03–1.31 0.014 HDL-C, per 5 mg/dL increase 0.82 0.68–0.99 0.041 eGFR, per 10 mL/min decrease 1.21 1.04–1.41 0.013 UACR, per 50 mg/g increase 1.24 1.06–1.46 0.008 Serum uric acid, per 1 mg/dL increase 1.32 1.04–1.69 0.024 hs-CRP, per 1 mg/L increase 1.19 1.05–1.35 0.006 In the illustrative multivariable analysis, HbA1c, LDL-C, decreasing eGFR, increasing UACR, serum uric acid and hs-CRP remained independently associated with cardiovascular complications. Higher HDL-C was associated with reduced odds of cardiovascular complications. The source model identified HbA1c as one of the strongest independent associations, with every 1% increase corresponding to approximately 58% higher odds. Table 3. Predictive Performance of Individual and Combined Biochemical Markers Predictor/Model AUC 95% CI Sensitivity (%) Specificity (%) HbA1c alone 0.77 0.71–0.84 72 70 LDL-C alone 0.70 0.63–0.77 68 65 UACR alone 0.74 0.67–0.81 71 69 HbA1c + LDL-C 0.81 0.75–0.87 76 73 HbA1c + LDL-C + UACR + hs-CRP 0.86 0.81–0.91 81 78 The combined model demonstrated better discriminatory performance than any individual marker. The four-marker model incorporating HbA1c, LDL-C, UACR and hs-CRP achieved the highest illustrative AUC of 0.86 and showed sensitivity of 81% and specificity of 78%.

The present illustrative analysis demonstrates that diabetic patients with cardiovascular complications have a significantly more adverse renal, metabolic and inflammatory biochemical profile than those without cardiovascular disease. Renal dysfunction represented one of the clearest differences between the groups. Mean serum creatinine was 1.28±0.46 mg/dL among patients with cardiovascular complications compared with 0.96±0.29 mg/dL among those without CVD. Mean eGFR was substantially lower in the CVD group at 69.4±19.7 mL/min/1.73 m² compared with 86.6±18.3 mL/min/1.73 m². These findings support the strong cardiorenal relationship described throughout the source thesis. UACR demonstrated a particularly marked between-group difference. Mean UACR was 112.6±96.5 mg/g in patients with CVD compared with 48.3±61.7 mg/g among those without cardiovascular complications. The source also reports that moderately or severely increased albuminuria was substantially more common in patients with CVD. This is clinically relevant because albuminuria may represent not only renal injury but also generalized endothelial and vascular dysfunction. The multivariable model further strengthened the importance of renal markers. Every 10 mL/min reduction in eGFR was associated with an adjusted odds ratio of 1.21, while each 50 mg/g increase in UACR was associated with an adjusted odds ratio of 1.24. This suggests that declining renal function and increasing albuminuria provide cardiovascular risk information independently of other included biochemical variables in the illustrative model. Serum uric acid was also independently associated with cardiovascular complications. The source reported a mean concentration of 6.8±1.6 mg/dL in the CVD group compared with 5.7±1.4 mg/dL in the non-CVD group. In the adjusted model, every 1 mg/dL increase was associated with an odds ratio of 1.32. Nevertheless, serum uric acid should be interpreted cautiously because it is influenced by renal function, metabolic factors and medication use. Inflammatory activity was also greater among patients with cardiovascular complications. Median hs-CRP was 4.8 mg/L with an IQR of 3.1–7.2 in the CVD group versus 2.3 mg/L with an IQR of 1.4–4.0 in the non-CVD group. Furthermore, each 1 mg/L increase in hs-CRP was associated with an adjusted OR of 1.19 in the illustrative regression model. An important finding was that no single biomarker achieved the discriminatory performance of the combined model. HbA1c alone had an AUC of 0.77, UACR 0.74 and LDL-C 0.70. Combining HbA1c and LDL-C increased the AUC to 0.81, while adding UACR and hs-CRP increased it further to 0.86. This supports the conceptual framework of diabetic cardiovascular disease as a multifactorial process involving glycaemic, lipid, renal and inflammatory pathways. The source thesis itself concludes that HbA1c remains important as an indicator of chronic glycaemic exposure, while UACR and eGFR should be interpreted as cardiovascular as well as renal risk markers. It also notes that combined biochemical models may offer better discrimination than individual parameters. Several limitations must be recognized. Because the design is cross-sectional, the observed associations cannot establish whether biomarker abnormalities preceded cardiovascular complications. In addition, biomarkers may be affected by antidiabetic drugs, statins, antihypertensive agents, renin-angiotensin system blockers and diuretics. hs-CRP is nonspecific, and serum uric acid is influenced by renal function and medications. External validation would also be required before applying a combined prediction model in clinical practice.

Diabetic patients with cardiovascular complications demonstrated significantly greater renal impairment, albuminuria, hyperuricaemia and inflammatory activity compared with diabetic patients without cardiovascular complications. Higher serum creatinine and UACR and lower eGFR were strongly associated with cardiovascular disease. HbA1c, LDL-C, eGFR, UACR, serum uric acid and hs-CRP remained independently associated with cardiovascular complications in the illustrative multivariable model, while higher HDL-C demonstrated a protective association. The combined biomarker model comprising HbA1c, LDL-C, UACR and hs-CRP demonstrated superior discriminatory performance compared with individual markers. These findings support the potential value of integrating glycaemic, lipid, renal and inflammatory parameters in cardiovascular risk assessment among patients with diabetes mellitus.

1. Rahimi-Sakak F, Maroofi M, Rahmani J, Bellissimo N, Hekmatdoost A. Serum uric acid and risk of cardiovascular mortality: a systematic review and dose-response meta-analysis of cohort studies of over a million participants. BMC Cardiovasc Disord. 2019;19(1):218. doi:10.1186/s12872-019-1215-z. 2. Cortese F, Giordano P, Scicchitano P, Faienza MF, De Pergola G, Calculli G, et al. Uric acid: from a biological advantage to a potential danger. A focus on cardiovascular effects. Vascul Pharmacol. 2019;120:106565. doi:10.1016/j.vph.2019.106565. 3. Cheng C, Liu Y, Sun X, Yin Z, Li H, Zhang M, et al. Dose-response association between the triglycerides: high-density lipoprotein cholesterol ratio and type 2 diabetes mellitus risk: the rural Chinese cohort study and meta-analysis. J Diabetes. 2019;11(3):183-192. doi:10.1111/1753-0407.12836. 4. Rana JS, Liu JY, Moffet HH, Sanchez RJ, Khan I, Karter AJ. Risk of cardiovascular events in patients with type 2 diabetes and metabolic dyslipidemia without prevalent atherosclerotic cardiovascular disease. Am J Med. 2020;133(2):200-206. doi:10.1016/j.amjmed.2019.07.003. 5. Jayakumari C, Jabbar PK, Soumya S, Jayakumar RV, Das DV, Girivishnu G, et al. Lipid profile in Indian patients with type 2 diabetes: the scope for atherosclerotic cardiovascular disease risk reduction. Clin Diabetes. 2020;38(4):299-306. doi:10.2337/cd19-0046. 6. Joseph JJ, Deedwania P, Acharya T, Aguilar D, Bhatt DL, Chyun DA, et al. Comprehensive management of cardiovascular risk factors for adults with type 2 diabetes: a scientific statement from the American Heart Association. Circulation. 2022;145(9):e722-e759. doi:10.1161/CIR.0000000000001040. 7. Unnikrishnan AG, Sahay RK, Phadke U, Sharma SK, Shah P, Shukla R, et al. Cardiovascular risk in newly diagnosed type 2 diabetes patients in India. PLoS One. 2022;17(3):e0263619. doi:10.1371/journal.pone.0263619. 8. Gedebjerg A, Bjerre M, Kjaergaard AD, Nielsen JS, Rungby J, Brandslund I, et al. CRP, C-peptide, and risk of first-time cardiovascular events and mortality in early type 2 diabetes: a Danish cohort study. Diabetes Care. 2023;46(5):1037-1045. doi:10.2337/dc22-1353. 9. Sattar N, McMurray JJV, Borén J, Rawshani A, Omerovic E, Berg N, et al. Twenty years of cardiovascular complications and risk factors in patients with type 2 diabetes: a nationwide Swedish cohort study. Circulation. 2023;147(25):1872-1886. doi:10.1161/CIRCULATIONAHA.122.063374. 10. Kanieeth D, Swaminathan K, Velmurugan G, Ramakrishnan A, Alexander T, Raghupathy AK, et al. Association between serum uric acid levels and cardiovascular risk factors among adults in India. Nutr Metab Cardiovasc Dis. 2023;33(7):1330-1338. doi:10.1016/j.numecd.2023.05.003. 11. Marx N, Federici M, Schütt K, Müller-Wieland D, Ajjan RA, Antunes MJ, et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44(39):4043-4140. doi:10.1093/eurheartj/ehad192. 12. American Diabetes Association Professional Practice Committee. Cardiovascular disease and risk management: Standards of Care in Diabetes—2024. Diabetes Care. 2024;47(Suppl 1):S179-S218. doi:10.2337/dc24-S010. 13. Wilson M, Al-Hamid A, Abbas I, Birkett J, Khan I, Harper M, et al. Identification of diagnostic biomarkers used in the diagnosis of cardiovascular diseases and diabetes mellitus: a systematic review of quantitative studies. Diabetes Obes Metab. 2024;26(8):3009-3019. doi:10.1111/dom.15593. 14. Borén J, Öörni K, Catapano AL. The link between diabetes and cardiovascular disease. Atherosclerosis. 2024;394:117607. doi:10.1016/j.atherosclerosis.2024.117607. 15. Sartore G, Piarulli F, Ragazzi E, Mallia A, Ghilardi S, Carollo M, et al. Circulating factors as potential biomarkers of cardiovascular damage progression associated with type 2 diabetes. Proteomes. 2024;12(4):29. doi:10.3390/proteomes12040029. 16. Piarulli F, Banfi C, Ragazzi E, Gianazza E, Munno M, Carollo M, et al. Multiplexed MRM-based proteomics for identification of circulating proteins as biomarkers of cardiovascular damage progression associated with diabetes mellitus. Cardiovasc Diabetol. 2024;23(1):36. doi:10.1186/s12933-024-02125-1. 17. Jin Q, Lau ESH, Luk AO, Tam CHT, Ozaki R, Lim CKP, et al. Circulating metabolomic markers linking diabetic kidney disease and incident cardiovascular disease in type 2 diabetes: analyses from the Hong Kong Diabetes Biobank. Diabetologia. 2024;67(5):837-849. doi:10.1007/s00125-024-06108-5. 18. Huang ZG, Gao JW, Zhang HF, You S, Xiong ZC, Wu YB, et al. Cardiovascular health metrics defined by Life's Essential 8 scores and subsequent macrovascular and microvascular complications in individuals with type 2 diabetes: a prospective cohort study. Diabetes Obes Metab. 2024;26(7):2673-2683. doi:10.1111/dom.15583. 19. Bazmandegan G, Dehghani MH, Karimifard M, Kahnooji M, Balaee P, Zakeri MA, et al. Uric acid to HDL ratio: a marker for predicting incidence of metabolic syndrome in patients with type II diabetes. Nutr Metab Cardiovasc Dis. 2024;34(4):1014-1020. doi:10.1016/j.numecd.2023.12.022.